{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:58:09Z","timestamp":1788321489294,"version":"build-2803163510"},"reference-count":22,"publisher":"Informa UK Limited","issue":"6","funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2019,6,3]]},"DOI":"10.1080\/03007995.2018.1558883","type":"journal-article","created":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T21:52:39Z","timestamp":1544910759000},"page":"1103-1110","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma"],"prefix":"10.1080","volume":"35","author":[{"given":"Xue","family":"Song","sequence":"first","affiliation":[{"name":"IBM Watson Health, Cambridge, MA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qayyim","family":"Said","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceutical Corporation, East Hanover, NJ, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oth","family":"Tran","sequence":"additional","affiliation":[{"name":"IBM Watson Health, Cambridge, MA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy A.","family":"Krueger","sequence":"additional","affiliation":[{"name":"Division of Neurology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bissler","sequence":"additional","affiliation":[{"name":"LeBonheur Children\u2019s Hospital and St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.10.013"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61279-9"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1269906"},{"key":"CIT0004","unstructured":"National Institute of Neurological Diseases and Stroke (NINDS). Tuberous Sclerosis Fact Sheet [Internet]. 2017 [cited 2018 Apr 14]. Available from: https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Tuberous-Sclerosis-Fact-Sheet"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-008-0832-y"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1991.tb37754.x"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2006.01.008"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2013.08.002"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02567.x"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-011-0123-z"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24523"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1159\/000320891"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.05.016"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1159\/000448293"},{"key":"CIT0015","unstructured":"Afinitor (everolimus) and Afinitor Disperz (everolimus tablets for oral suspension). Prescribing information [Internet]. 2016 [cited 2018 Apr 14]. Available from: https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/afinitor.pdf [Last accessed April 14, 2018]"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61134-9"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001671"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61767-X"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu013"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182815428"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"CIT0022","doi-asserted-by":"crossref","unstructured":"Princic N, Brouillette M, Tang DH, et\u00a0al. Analysis of real world patient compliance to everolimus-based therapy among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+\/HER2\u2212) metastatic breast cancer (mBC). Poster presented at: American Society of Clinical Oncology (ASCO) 2017 Annual Meeting; Chicago, IL.","DOI":"10.1200\/JCO.2017.35.15_suppl.e12546"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2018.1558883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T23:16:48Z","timestamp":1599261408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2018.1558883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,3]]}},"alternative-id":["10.1080\/03007995.2018.1558883"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2018.1558883","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}